The 20 Best Classical Hodgkin Lymphoma Doctors near Columbia, MD

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Advanced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

Learn more at marylandoncology.com. Dr. Sastry is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain.

Dr. Brian Holly is an assistant professor of radiology and radiological science. Dr. Holly's clinical focus lies in venous thromboembolic disease. He specializes in the diagnosis and treatment of deep venous thrombosis, pulmonary embolism, post thrombotic syndrome; advanced venous interventions including prostatic artery embolization (PAE); IVC filter removal; treatment of vascular malformations; treatment of uterine fibroids and advanced biliary interventions. Dr. Holly received his M.D. from the University of Maryland School of Medicine in 2007. He completed an internship in internal medicine at Mercy Medical Center in 2008. He completed residency in radiology in 2012 at the University of Maryland Medical Center. This was followed by a fellowship in vascular and interventional radiology in 2013 at The Johns Hopkins Hospital. He is a member of the Society of Interventional Radiology. Recent News Articles and Media Coverage Minimally Invasive Treatment for Uterine Fibroids Webinar Uterine fibroids are non-cancerous growths that develop from the muscle tissue of the uterus. Interventional radiologist, Brian Holly, M.D., and gynecologist, Khara Simpson, M.D., hosted this interactive webinar to discuss a non-surgical alternative for uterine fibroids called uterine fibroid embolization. Dr. Holly is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Deep Vein Thrombosis, Enlarged Prostate (BPH), Cholangiocarcinoma (Bile Duct Cancer), Gastrostomy, and Liver Embolization.

Gayatri Nimmagadda is a Hematologist and a Hematologist Oncology provider in Columbia, Maryland. Dr. Nimmagadda is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Pleuropulmonary Blastoma.

Najeff Waseem is a Hematologist and a Hematologist Oncology provider in Columbia, Maryland. Dr. Waseem is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Thrombocytopenia, Agranulocytosis, Chronic Familial Neutropenia, and Triple-Negative Breast Cancer.

Laura Schoch, C.R.N.P., is an internal medicine provider at Johns Hopkins Community Physicians. N.P. Schoch earned her masters of science in nursing (MSN) in 2014 from the University of Maryland (IMD) with an adult and gerontology focus. She also completed an oncology certificate program while at UMD, and was a recipient of the American Cancer Society Graduate Scholarship in Cancer Nursing Practice in 2012. N.P. Schoch is a licensed nurse practitioner in Maryland. N.P. Schoch has extensive oncology experience and is especially interested in cancer prevention and survivorship. She is excited to partner with her patients to promote health, prevent disease and facilitate optimal aging across the lifespan. She lives with her husband, two daughters, one cat and many plants in Ellicott City. Ms. Schoch is rated as an Advanced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Classical Hodgkin Lymphoma, T-Cell Lymphoma, Marginal Zone Lymphoma (MZL), and Smoldering Multiple Myeloma.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as a Distinguished provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as a Distinguished provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Laura Hostovich is a Nurse Practitioner in Columbia, Maryland. Ms. Hostovich is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Smoldering Multiple Myeloma, Classical Hodgkin Lymphoma, and Febrile Neutropenia.

Ari Elman is an Oncologist in Columbia, Maryland. Dr. Elman has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Myelodysplastic Syndrome (MDS).

Julie Baker is a Nurse Practitioner in Columbia, Maryland. Ms. Baker is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Smoldering Multiple Myeloma, Classical Hodgkin Lymphoma, Myeloproliferative Neoplasms (MPN), and T-Cell Lymphoma.

Mian Khalid is a Hematologist in Columbia, Maryland. Dr. Khalid is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Acquired Hemophilia, Smoldering Multiple Myeloma, and Relapsing Multiple Sclerosis (RMS).

Dr. Stacy Cooper is the Director of the Pediatric Hematologic Malignancy Program, Director of the Pediatric Hematology/Oncology Fellowship Program, and Clinical Director of the Pediatric Oncology Inpatient Program at the Johns Hopkins School of Medicine. Dr. Cooper received her undergraduate degree in Biology and Spanish at the University of Notre Dame. She earned her M.D. at SUNY Upstate Medical University. She completed her general pediatric residency and chief residency at the Johns Hopkins School of Medicine. She completed her pediatric hematology-oncology fellowship with the Johns Hopkins-National Institutes of Health. Dr. Cooper joined the Johns Hopkins faculty in 2015. Her research focuses on clinical research in acute lymphoblastic leukemia, as well as medical education scholarship related to fellowship training. Dr. Cooper is a member of the American Board of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology Oncology and the Association of Pediatric Program Directors. Dr. Cooper is rated as an Advanced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, and Bone Marrow Transplant.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Myelodysplastic Syndrome (MDS).

Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health. Dr. Ali is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Gastrostomy.